Alpelisib + letrozole in patients with PIK3CA-mutated, hormone-receptor positive (HR+), human epidermal growth factor receptor-2-negative (HER2-) advanced breast cancer (ABC) previously treated with a cyclin-dependent kinase 4/6 inhibitor (CDK4/6i) + fulvestrant: BYLieve study results Meeting Abstract
| Authors: | Rugo, H. S.; Lerebours, F.; Juric, D.; Turner, N.; Chia, S.; Drullinsky, P.; Prat, A.; Vázquez, R. V.; Akdere, M.; Arce, C.; Shen, Y. M.; Ciruelos, E. |
| Abstract Title: | Alpelisib + letrozole in patients with PIK3CA-mutated, hormone-receptor positive (HR+), human epidermal growth factor receptor-2-negative (HER2-) advanced breast cancer (ABC) previously treated with a cyclin-dependent kinase 4/6 inhibitor (CDK4/6i) + fulvestrant: BYLieve study results |
| Meeting Title: | 43rd Annual San Antonio Breast Cancer Symposium (2020 SABCS) |
| Journal Title: | Cancer Research |
| Volume: | 81 |
| Issue: | 4 Suppl. |
| Meeting Dates: | 2020 Dec 8-11 |
| Meeting Location: | San Antonio, TX |
| ISSN: | 0008-5472 |
| Publisher: | American Association for Cancer Research |
| Date Published: | 2021-02-01 |
| Language: | English |
| ACCESSION: | WOS:000618737700186 |
| PROVIDER: | wos |
| DOI: | 10.1158/1538-7445.SABCS20-PD2-07 |
| Notes: | Meeting Abstract: PD2-07 -- This symposium was held virtually due to COVID-19 -- Source: Wos |
